1 The results of cotrimoxazole (CTZ) co-administration (15 mg kg-1 trimethoprim + 40 mg kg-1 sulphamethoxazole) on plasma concentration and various pharmacokinetic parameters of rifampicin (RIF, 24 mg kg-1) and isoniazid (INH, 14 mg kg-1) were studied.
2 In the test group (n = 6), CTZ was administered on the 24th day of antitubercular treatment (ATT) and given for 7 d.
3 At the end of concurrent treatment with CTZ, RIF half-life (t½) and plasma concentration were both increased. However, there was no effect on INH half-life and plasma concentration.
Get full access to this article
View all access options for this article.
References
1.
Baciewicz AM , Self TH & BeKemeyer WB. Update on Rifampicin in drug interactions. Archives ofInternal Medicine1987; 147: 565-68.
2.
Uppal R., Bhowmik SR, Malik SK, Jindal SK & Sharma PLDrug usage in chest diseases. International Journal of Clinical Pharmacology Therapy and Toxicology1988; 26: 33-5.
3.
Bhatia RS, Uppal R., Malhi R., Behera D. & Jindal SKDrug interaction between rifampicin and cotrimoxazole in patients with tuberculosis . Human & Experimental Toxicology1991 ; 10: in press.
4.
Paget GE and Barnes JM In: Evaluation of Drug Activities: Pharmacometrics, eds, Lawrence DR and Bacharach AL, Vol1. New York: Academic Press, 1964.
5.
McConnel JB, Smith H., Davis M. & Williams R.Plasma rifampicin assay of an improved solvent extraction technique. British Journal of Clinical Pharmacology1979; 8: 506-7.
6.
Scott ME & Wright CRFluorometeric determination of isonicotinic acid hydrozide in serum. Journal of Laboratory and Clinical Medicine1967; 20: 355-60.
7.
Norden CW & Keleti E.Treatment of experimental staphylococcal osteomyelitis with rifampicin and trimethoprim alone and in combination. Antimicrobial Agents and Chemotherapy1980; 17: 591.
8.
Shutkin G., Schecter GF & Hopewell PCThe results of 9-month isoniazid-rifampicin therapy for pulmonary tuberculosis under programme conditions in San Francisco. American Review of Respiratory Diease1988; 138: 1622-4.
9.
Wing Lmh & Miners JOCTZ as an inhibitor of oxidative drug metabolism, effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition. British Journal of Clinical Pharmacology1985; 20; 482-5.
